278 related articles for article (PubMed ID: 31652074)
41. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
[TBL] [Abstract][Full Text] [Related]
42. [Radionuclide therapy for neuroendocrine tumours].
Mortensen J; Oturai P; Højgaard L; Knigge U; Hansen CP; Martiný L; Rasmussen P; Kjaer A
Ugeskr Laeger; 2010 Oct; 172(43):2950-3. PubMed ID: 21040673
[TBL] [Abstract][Full Text] [Related]
43. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
[TBL] [Abstract][Full Text] [Related]
44. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
45. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
46. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
47. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
Sansovini M; Severi S; Ambrosetti A; Monti M; Nanni O; Sarnelli A; Bodei L; Garaboldi L; Bartolomei M; Paganelli G
Neuroendocrinology; 2013; 97(4):347-54. PubMed ID: 23392072
[TBL] [Abstract][Full Text] [Related]
48. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
49. How We Do It: A Multidisciplinary Approach to
Burkett BJ; Dundar A; Young JR; Packard AT; Johnson GB; Halfdanarson TR; Eiring RA; Gansen DN; Patton CM; Kendi AT
Radiology; 2021 Feb; 298(2):261-274. PubMed ID: 33231532
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
52. Evolution of Neuroendocrine Tumor Therapy.
O'Dorisio TM; Harris AG; O'Dorisio MS
Surg Oncol Clin N Am; 2020 Apr; 29(2):145-163. PubMed ID: 32151353
[TBL] [Abstract][Full Text] [Related]
53. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
54. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
[TBL] [Abstract][Full Text] [Related]
55. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
[TBL] [Abstract][Full Text] [Related]
56. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
57. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
[TBL] [Abstract][Full Text] [Related]
58. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
59. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with
Hope TA; Abbott A; Colucci K; Bushnell DL; Gardner L; Graham WS; Lindsay S; Metz DC; Pryma DA; Stabin MG; Strosberg JR
J Nucl Med; 2019 Jul; 60(7):937-943. PubMed ID: 31263080
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
